MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
85.79
+0.10
+0.12%
After Hours: 85.01 -0.78 -0.91% 19:34 09/28 EDT
OPEN
84.72
PREV CLOSE
85.69
HIGH
87.12
LOW
84.00
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
110.18
52 WEEK LOW
15.49
MARKET CAP
7.56B
P/E (TTM)
-36.9434
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SYRE last week (0921-0925)?
Weekly Report · 20h ago
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)
TipRanks · 1d ago
Spyre Therapeutics (SYRE) Dropped, So What Is Behind The Latest Attention?
Simply Wall St · 4d ago
Is Positive Trial Data Altering The Investment Case For Spyre Therapeutics (SYRE)?
Simply Wall St · 09/21 18:25
Wedbush biotech analyst holds an analyst/industry conference call
TipRanks · 09/21 13:55
Weekly Report: what happened at SYRE last week (0914-0918)?
Weekly Report · 09/21 09:41
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
Weekly Report: what happened at SYRE last week (0907-0911)?
Weekly Report · 09/14 09:43
More
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.